Drug Trial Radar · NCT00610051
ALP-1 Continuous Intravenous Infusion to Maintain Clinical Stability in Advanced Heart Failure
Last checked: Nov 19, 2026Latest source record: Dec 15, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
600
Planned (sponsor's estimate)
Start
Oct 2026
Primary completion
Nov 2029
Study completion Dec 2030
Sponsor
- Lead sponsor
- Biopeutics Co., LtdIndustry
- Sponsor type
- Industry
- First posted
- Feb 7, 2008
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a global multicenter, doubleblind, placebo-controlled, randomized, parallel-group study that compares ALP-1 given in a continuous infusion ( compared to placebo), 250mcg/day on majore outcomes up to 6 months after randomization in participants with advanced HF with reduced ejection fraction(HFrEF).
Conditions
- End Stage Cardiac Failure
- HFrEF - Heart Failure With Reduced Ejection Fraction
- NYHF Class III-IV
Interventions
AlprostadilDrug
central venous access continuous delivery with 500mcg/48 hours in active arm
Primary outcomes
What the sponsor says the trial is designed to measure.
- Time to all-cause mortality (defined as death, heart transplant, LVAD placement, mechanical circulatory support, or HF event(* hospitalization for HF or unplanned intravenous therapy for HF, ie diurectics, inotropes, vassopressors, or vasodilators.)Time frame: 6 months infusion
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Medical university Vienna
Vienna, Austria
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.